Summit Therapeutics: Emerging Competition for Merck

This chapter examines the strong stock market performance of Summit Therapeutics following promising results from a lung cancer drug trial, positioning it as a competitor to Merck's Keytruda. The discussion also explores Merck's financial reliance on Keytruda and the potential push for strategic mergers and acquisitions in the evolving pharmaceutical landscape.